Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024
06 May 2024
ImmunotherapyCell TherapyPhase 1AACR
PHILADELPHIA, May 6, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that an abstract has been accepted for oral presentation at the upcoming American Society of Gene & Cell Therapy 2024 (ASGCT 2024), to be held in Baltimore on May 7-11, 2024.
Presentation Details
Title: Preclinical Specificity and Potency Evaluation of a Novel CD19-specific KIR-CAR T Cell Therapy (SynKIR™-310)
Abstract Number: 6332
Date and Time: Thursday, May 9th: 5:00 – 5:15 p.m.
Presenting Author: Nora Yucel, Ph.D., Translational Scientist at Verismo Therapeutics
Description: We have previously shown that a novel killer immunoglobulin-like receptor (KIR)-based CAR expressed in T cells as a multichain receptor with DAP12 (KIR-CAR T) has enhanced anti-tumor activity compared to conventional second-generation CAR T cells in several preclinical solid tumor models. These data suggest the KIR-CAR platform may show improved activity in aggressive lymphoma. We will present preclinical data on the in vitro and in vivo studies of the novel KIR-CAR T cell therapy, SynKIR™-310 with the new proprietary CD19 binder (DS191). The preclinical study data demonstrates that high CD19 antigen sensitivity, specificity, and potency of the novel binder DS191 combined with KIR-CAR supports SynKIR™-310 as a promising T cell therapy against CD19-positive malignanciesCD19-positive malignancies.
About the KIR-CAR Platform
The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation seen in conventional CAR T cells separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to regression of solid tumors and blood cancers in preclinical models that are resistant to traditional CAR T cell therapies. The KIR-CAR platform is being investigated in combination with many additional emerging technologies to potentially provide the next-generation multimodal targeted immunotherapy for patients in need.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in multi-chain KIR-CAR technology, with its first asset SynKIR™-110 currently in a first-in-human Phase 1 clinical trial. Verismo's second asset SynKIR™-310 is rapidly advancing towards a Phase 1 clinical trial as well. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve T cell persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically for treating advanced solid tumors and B cell associated disorders and malignancies, areas of high unmet medical need. For more information, visit:
CONTACT: Raymond Luke; raymond.luke@verismotherapeutics.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.